National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedGreen TC, Potter N, Bratberg J
Detecting naloxone prejudices in the pharmacy setting.
This survey asked pharmacists how concerned they would be about dispensing pain medications (or Suboxone) to customers who are getting or already have naloxone. Fifty-nine percent of respondents indicated no or little increased concern about dispensing either medication to a known naloxone recipient. Greater concern was reported by pharmacists when considering dispensing pain medications to a known naloxone recipient.
AHRQ-funded; Letter related to AHRQ-funded MOON project (HS024021).
Citation: Green TC, Potter N, Bratberg J .
Detecting naloxone prejudices in the pharmacy setting.
J Am Pharm Assoc 2017 Mar - Apr;57(2s):S10-s11. doi: 10.1016/j.japh.2016.12.068.
.
.
Keywords: Medication, Provider: Pharmacist, Social Media, Substance Abuse
Green TC, Case P, Fiske H
Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
This study examined perceptions and experiences of pharmacy naloxone from people with opioid use disorder, patients taking chronic opioids for pain, caregivers of opioid users, and pharmacists. It found that consumer groups differed in awareness of naloxone and availability at pharmacies, but all groups expressed support for the pharmacist's role and preferences for a universal offer of naloxone based on clear criteria.
AHRQ-funded; HS024021.
Citation: Green TC, Case P, Fiske H .
Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
J Am Pharm Assoc 2017 Mar - Apr;57(2s):S19-S27.e4. doi: 10.1016/j.japh.2017.01.013.
.
.
Keywords: Opioids, Provider: Pharmacist, Social Stigma, Substance Abuse